What long-term trials found
The controlled evidence for long-term use at the hair loss dose runs to five years and is reassuring on common side effects. In the five-year extension of the main trials, the investigators reported that finasteride 1 mg was generally well tolerated and that no new safety concerns were identified. In the Propecia label, the rate of each sexual side effect fell to 0.3% or less by the fifth year.
Trials of this size cannot detect rare problems. Most of the warnings below come from larger prostate studies or from reports sent in after approval, which can flag a risk but cannot measure how common it is. Everyday effects are on the side effects page.
High-grade prostate cancer: PCPT and the 2011 FDA communication
A large prevention trial found that finasteride 5 mg reduced prostate cancers overall but increased the most aggressive ones, and the FDA added a warning in 2011. The Prostate Cancer Prevention Trial (PCPT, summarized under studies) assigned 18,882 men aged 55 and over to finasteride 5 mg or placebo for seven years.
| PCPT result | Finasteride 5 mg | Placebo |
|---|---|---|
| Any prostate cancer (men in the final analysis) | 18.4% | 24.4% |
| Gleason score 8 to 10 cancer | 1.8% | 1.1% |
| Survival at 15 years | 78.0% | 78.2% |
The Gleason score grades how aggressive a cancer looks under the microscope, and 8 to 10 is the high end. On June 9, 2011, the FDA announced that labels for the whole drug class had been revised to describe this risk, which it said appears to be low. A follow-up of up to 18 years found no significant difference in overall survival. The dose studied was five times the hair loss dose, and the label says the significance for men taking 1 mg is unknown. PSA screening is covered under interactions and lab tests.
Male breast cancer reports
Male breast cancer has been reported in men taking finasteride, and the label says the relationship to long-term use is unknown. The trial counts point in different directions:
- MTOPS (3,047 men): 4 cases in men who received finasteride, none in men who did not.
- PLESS (3,040 men): 2 cases on placebo, none on finasteride.
- PCPT (18,882 men): 1 case on finasteride and 1 on placebo.
The label asks men to report any breast lump, pain or nipple discharge promptly.
Fertility and semen
Finasteride has small measurable effects on semen that reversed after stopping in the studies cited in the label. In a study of healthy men taking 1 mg a day for 48 weeks, the median drop in ejaculate volume was 0.3 mL (11%), against 0.2 mL (8%) with placebo. At 5 mg a day, two other studies cited in the label found a larger median drop of about 0.5 mL (25%) compared with placebo, which reversed after treatment was stopped.
After approval, the label added reports of male infertility and poor semen quality, noting that semen quality normalized or improved after finasteride was discontinued. Risks to a pregnancy from handling tablets are on the finasteride and women page.
Depression and suicidality
Depression and suicidal thoughts are listed on the label as reports received after approval, and the wording has been strengthened over time. The version of the Propecia label revised in April 2012 listed depression only. The current label lists depression, suicidal ideation and behavior.
A Canadian study of 93,197 men aged 66 and older who started a drug in this class for prostate enlargement found no increase in suicide, but did find a higher risk of self-harm and of depression in the first 18 months. Those were older men on prostate doses, and this type of study cannot prove cause.
If your mood drops or you have thoughts of self-harm after starting finasteride, contact your prescriber promptly. In the US you can call or text 988 at any time.
Common questions
Does finasteride cause prostate cancer?
In PCPT, finasteride 5 mg lowered the overall rate of prostate cancer but raised the rate of high-grade cancer from 1.1% to 1.8%. Long-term follow-up found no difference in survival.
Can finasteride cause infertility?
Reports of infertility and poor semen quality have been received, with improvement after stopping. Controlled studies found small decreases in ejaculate volume that reversed after stopping.
Should I worry about depression on finasteride?
Depression and suicidal thoughts are listed on the label from post-approval reports. The absolute risk is not known. Anyone who notices a change in mood after starting should contact the prescriber.
Sources
- Organon. Propecia (finasteride) tablets 1 mg, full prescribing information and patient information. DailyMed, National Library of Medicine. DailyMed: Propecia label
- Finasteride Male Pattern Hair Loss Study Group. Long-term (5-year) multinational experience with finasteride 1 mg in the treatment of men with androgenetic alopecia. European Journal of Dermatology, 2002. PubMed 11809594
- Thompson IM, Goodman PJ, Tangen CM, et al. The influence of finasteride on the development of prostate cancer. New England Journal of Medicine, 2003. PubMed 12824459
- Thompson IM Jr, Goodman PJ, Tangen CM, et al. Long-term survival of participants in the Prostate Cancer Prevention Trial. New England Journal of Medicine, 2013. PubMed 23944298
- US Food and Drug Administration. Drug Safety Communication: 5-alpha reductase inhibitors (5-ARIs) may increase the risk of a more serious form of prostate cancer, June 9, 2011 (archived copy). FDA safety communication
- Welk B, McArthur E, Ordon M, et al. Association of suicidality and depression with 5-alpha reductase inhibitors. JAMA Internal Medicine, 2017. PubMed 28319231
- Merck. Propecia prescribing information, revised April 2012. Drugs@FDA, US Food and Drug Administration. 2012 Propecia label (PDF)